News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: jq1234 post# 259900

Saturday, 03/26/2016 12:59:06 PM

Saturday, March 26, 2016 12:59:06 PM

Post# of 347009
Medarex was in collaborations with Peregrine before BMY buys them out and you think these were the beginning stages of BMY finding out how valuable PS Targeting truly was? I think so

BMY looked deep under the hood of Medarex and all what was going on with Peregrine collaborations and all it takes is one name to force it all to surface

I'd sit back and enjoy the turbulence, because maybe this is all what ultimately led to the sabotage of CSM where ex-BMY CEO Gerald Finken was in a position to help and Jeanetter Bleecker was in a position to accept a bribe and why else would she leave an industry in the Midwest where normally one stays in her position

All it takes is one and I guess things take time

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y